Tocopherol from seeds of Cucurbita pepo against diabetes: Validation by invivo experiments supported by computational docking

Journal of the Formosan Medical Association

Volumn 112, Issue 11, 2013, Pages 676-690

  Bharti, Sudhanshu Kumar ^a   Kumar, Amit ^b   Sharma, Neeraj Kumar ^a   Prakash, Om ^b   Jaiswal, Sudhir Kumar ^a   Krishnan, Supriya ^c   Gupta, Ashok Kumar ^a,d   Kumar, Awanish ^d,e  

^a PATNA UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c BANARAS HINDU UNIVERSITY   (India)

^d National Institute of Pharmaceutical Education and Research (NIPER)   (India)

^e NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Antidiabetic; Cucurbita pepo seed; Docking; HPLC; PPAR

Indexed keywords

ALPHA TOCOPHEROL; BETA TOCOPHEROL; DELTA TOCOPHEROL; DIPEPTIDYL PEPTIDASE IV; GAMMA TOCOPHEROL; GLUCAGON LIKE PEPTIDE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLOXAMER; PROTEIN TYROSINE PHOSPHATASE 1B; TOCOPHEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CUCURBITA PEPO; DRUG ISOLATION; DRUG MECHANISM; HISTOPATHOLOGY; IN VIVO STUDY; LIPID PEROXIDATION; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PLANT SEED; RAT;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; CUCURBITA; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; MALE; MODELS, THEORETICAL; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT PREPARATIONS; RATS; RATS, WISTAR; SEEDS; TOCOPHEROLS; TREATMENT OUTCOME;

EID: 84887015763     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.08.003     Document Type: Article

References (72)

1. Nyenwe E.A., Jerkins T.W., Umpierrez G.E., Kitabchi A.E. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011, 60:1-23.
2. Vats R.K., Kumar V., Kothari A., Mital A., Ramachandran U. Emerging targets for diabetes. Curr Sci 2005, 88:241-249.
3. Chang C.H., Jiang Y.D., Chung C.H., Ho L.T., Chuang L.M. National trends in antidiabetic treatment in Taiwan, 2000-2009. J Formos Med Assoc 2012, 111:617-624.
4. Rosen C.J. Revisiting the rosiglitazone story - lessons learned. N Engl J Med 2010, 363:803-806.
5. Bharatam P.V., Patel D.S., Adane L., Mittal A., Sundriyal S. Modeling and informatics in designing anti-diabetic agents. Curr Pharm Des 2007, 13:3518-3530.
6. Waku T., Shiraki T., Oyama T., Maebara K., Nakamori R., Morikawa K. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. EMBO J 2010, 29:3395-3407.
7. Bharti S.K., Krishnan S., Kumar A., Rajak K.K., Murari K., Bharti B.K., et al. Antidiabetic activity and molecular docking of fructooligosaccharides produced by Aureobasidium pullulans in poloxamer-407-induced T2DM rats. Food Chem 2013, 136:813-821.
8. Bharti S.K., Krishnan S., Kumar A., Rajak K.K., Murari K., Bharti B.K., et al. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: investigation by experimental validation and molecular docking. Phytomedicine 2012, 20:24-31.
9. Combs A.P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 2010, 53:2333-2344.
10. Sutton J.M., Clark D.E., Dunsdon S.J., Fenton G., Fillmore A., Harris N.V., et al. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2012, 22:1464-1468.
11. Heinrich M., Barnes J., Gibbons S., Williamson E.M. Fundamentals of pharmacognosy and phytotherapy 2004, Churchill Livingstone, Edinburgh.
12. Applequist W.L., Avula B., Schaneberg B.T., Wang Y.H., Khan I.A. Comparative fatty acid content of seeds of four Cucurbita species grown in a common (shared) garden. J Food Comp Analy 2006, 19:606-611.
13. Xanthopoulou M.N., Nomikos T., Fragopoulou E., Antonopoulou S. Antioxidant and lipoxygenase inhibitory activities of pumpkin seed extracts. Food Res Inter 2009, 42:641-646.
14. Stevenson D.G., Eller F.J., Wang L., Jane J.L., Wang T., Inglett G.E. Oil and tocopherol content and composition of pumpkin seed oil in 12 cultivars. J Agric Food Chem 2007, 55:4005-4013.
15. Glew R.H., Glew R.S., Chuang L.T., Huang Y.S., Millson M., Constans D. Amino acid, mineral and fatty acid content of pumpkin seeds (Cucurbita sp.) and Cyperus esculentus nuts in the Republic of Niger. Plant Foods Hum Nutr 2006, 61:51-56.
16. Al-Zuhair H., Abdel-Fattah A.A., Abd-el-Latif H.A. Efficacy of simvastatin and pumpkin-seed oil in the management of dietary-induced hypercholesterolemia. Pharm Res 1997, 35:403-408.
17. Makni M., Fetoui H., Gargouri N.K., Garoui E.M., Jaber H., Makni J., et al. Hypolipidemic and hepatoprotective effects of flax and pumpkin seed mixture rich in ω-3 and ω-6 fatty acids in hypercholesterolemic rats. Food Chem Toxicol 2008, 46:3714-3720.
18. Hong L.H. Effect of pumpkin extracts on tumor growth inhibition in S180-bearing mice. Pract Prev Med 2005, 12:745-747.
19. Park S.C., Lee J.R., Kim J.Y. Pr-1, a novel antifungal protein from pumpkin rinds. Biotechnol Lett 2010, 32:125-130.
20. Fruhwirth G.O., Hermetter A. Seeds and oil of the Styrian oil pumpkin: Components and biological activities. Eur J Lipid Sci Technol 2007, 109:1128-1140.
21. Caili F., Huan S., Quanhong L. A review on pharmacological activities and utilization technologies of pumpkin. Plant Foods Hum Nutr 2006, 61:73-80.
22. Xia T., Wang Q. Antihyperglycemic effect of Cucurbita ficifolia fruit extract in streptozotocin-induced diabetic rats. Fitoterapia 2006, 77:530-533.
23. Kwon Y.I., Apostolidis E., Kim Y.C., Shetty K. Health benefits of traditional corn, beans, and pumpkin: invitro studies for hyperglycemia and hypertension management. J Med Food 2007, 10:266-275.
24. Tarhan L., Kayali H.A., Urek R.O. Invitro antioxidant properties of Cucurbita Pepo L. male and female flowers extracts. Plant Foods Hum Nutr 2007, 62:49-51.
25. Parry J.W., Cheng Z., Moore J., Yu L.L. Fatty acid composition, antioxidant properties, and antiproliferative capacity of selected cold-pressed seed flours. J Am Oil Chem Soc 2008, 85:457-464.
26. Wasan K.M., Subramanian R., Kwong M., Goldberg I.J., Wright T., Johnston T.P. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Pharm Sci 2003, 6:189-197.
27. McGann M. FRED and HYBRID docking performance on standardized datasets. J Comp-Aided Mol Des 2012, 26:687-699.
28. McGann M. FRED pose prediction and virtual screening accuracy. J Chem Informa Model 2011, 51:578-596.
29. Bryant S.H., Bolton E., Wang Y., Thiessen P.A. PubChem: Integrated platform of small molecules and biological activities. Ann Rep in Comp Chem 4, chap12 2008, Am Chem Soc, Washington, DC.
30. Guiraud J. "Microbiologie alimentaire - Rappels de microbiologie générale" 1998, Dunod, France.
31. Murkovic M., Piironen V., Lampi A.M., Kraushofer T., Sontag G. Changes in chemical composition of pumpkin seeds during the roasting process for production of pumpkin seed oil (Part 1: Non-volatile compounds). Food Chem 2004, 84:359-365.
32. Animal and vegetable fats and oils-determination of tocopherol and tocotrienol contents by high-performance liquid chromatography 2006, ISO 9936.
33. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
34. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265.
35. Prabhakar K.R., Veerapur V.P., Parihar K.V., Priyadarsini K.I., Rao B.S., Unnikrishnan M.K. Evaluation and optimization of radioprotective activity of Coronopus didymus Linn. in gamma-irradiated mice. Int J Radiat Biol 2006, 82:525.
36. Gelvan D., Saltman P. Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay. Biochim Biophys Acta 1990, 1035:353.
37. Berman H.M. The protein data bank. Nucleic Acids Res 2000, 28:235-242.
38. Chemaxon. http://www.chemaxon.com [Online; accessed 09.9.12].
39. Openeye. http://www.eyesopen.com [Online; accessed 04.3.12].
40. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996, 17:490-519.
41. OEChem MolProp ToolKit (version 2.1.5), http://www.eyesopen.com.
42. OEChem Shape ToolKit (version 1.9.0), http://www.eyesopen.com.
43. Aertgeerts K., Ye S., Tennant M.G., Kraus M.L., Rogers J., Sang B.C., et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004, 13:412-421.
44. Mahindroo N., Peng Y.H., Lin C.H., Tan U.K., Prakash E., Lien T.W., et al. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. J Med Chem 2006, 49:6421-6424.
45. Klopfenstein S.R., Evdokimov A.G., Colson A.O., Fairweather N.T., Neuman J.J., Maier M.B., et al. 1,2,3,4-Tetrahydro-isoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors. Bioorg Med Chem Lett 2006, 16:1574-1578.
46. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
47. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proceed Natl Acad Sci USA 1999, 96:6102-6106.
48. Zhang X., Li X., Wang R. Interpretation of the binding affinities of PTP1B inhibitors with the MM-GB/SA method and the X-score scoring function. J Chem Inf Model 2009, 49:1033-1048.
49. Tuzmen C., Erman B. Identification of ligand binding sites of proteins using the Gaussian Network model. PLoS One 2011, 6:e16474.
50. http://www.ccdc.cam.ac.uk/products/life_sciences/gold/case_studies/flexible_sidechains/.
51. David J.R., Tanimoto T.T. A computer program for classifying plants. Science 1960, 132:1115-1118.
52. David R., Mathew H. Extended-connectivity fingerprints. J Chem Inform Model 2010, 50:742-754.
53. Stierand K., Rarey M. PoseView-molecular interaction patterns at a glance. J Cheminform 2010, 2:50.
54. Johnston T.P., Goldberg I.J. Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss. J Pharm Pharmacol 2006, 58:1099-1105.
55. Xu G.H. A study of the possible antitumour effect and immune-competence of pumpkin polysaccharide. J Wuhan Prof Med Coll 2000, 28:1-4.
56. Murkovic M., Mulleder U., Neunteufl H. Carotenoid content in different varieties of pumpkins. J Food Comp Anal 2002, 15:633-638.
57. Kamal-Eldin A., Andersson R. A multivariate study of the correlation between tocopherol content and fatty acid composition in vegetable oils. J Am Oil Chem Soc 1997, 74:375-376.
58. Kielgast U., Holst J.J., Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011, 60:1599-1607.
59. Sedigheh A., Jamal M.S., Mahbubeh S., Somayeh K., Mahmoud R., Azadeh A., et al. Hypoglycaemic and hypolipidemic effects of pumpkin (Cucurbita pepo L.) on alloxan-induced diabetic rats. Afr J Pharm Pharmacol 2011, 5:2620-2626.
60. Mohajeri D., Ghafour M., Doustar Y. Antihyperglycemic and pancreas-protective effects of Crocus sativus L. (saffron) stigma ethanolic extract on rat with alloxan-induced diabetes. J Biol Sci 2009, 1-9.
61. Hii C.S., Howell S.L. Effects of epicatechin on rat islets of Langerhans. Diabetes 1984, 33:291-296.
62. Abdel-Hassan I.A., Abdel-Barry J.A., Mohammeda S.T. The hypoglycemic and antihyperglycaemic effect of Citrullus colocynthis fruit aqueous extract in normal and alloxan diabetic rabbits. J Ethnopharmacol 2000, 71:325-330.
63. Rauter A.P., Martins A., Borges C., Mota-Filipe H., Pinto R., Sepodes B., et al. Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats. Phytother Res 2010, 24:133-138.
64. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 2000, 24:297-302.
65. Murkovic M., Pfannhauser W. Stability of pumpkin seed oil. Eur J Lipid Sci Technol 2000, 102:607-611.
66. Matus Z., Molnár P., Szabó L.G. Main carotenoids in pressed seeds (Cucurbitae semen) of oil pumpkin (Cucurbita pepo). Acta Pharm Hung 1993, 63:247-256.
67. Bombardelli E., Morazzoni P. Curcubita pepo L. Fitoterapia 1997, 68:291.
68. Wagner H., Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009, 16:97-110.
69. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery. Adv Drug Deliv Rev 1997, 23:3-25.
70. Lipinski C.A. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 2003, 8:12-16.
71. Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 2008, 12:306-317.
72. Kelder J., Grootenhuis P.D., Bayada D.M., Delbressine L.P., Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999, 16:1514-1519.